In this phase 1 trial, treatment of patients with ER+HER2− metastatic breast cancer with a selective catalytic inhibitor of the lysine acetyltransferase KAT6 shows a manageable safety profile and encouraging preliminary clinical efficacy.
- Toru Mukohara
- Yeon Hee Park
- Patricia M. LoRusso